Mkts

C4 Therapeutics, Inc.

NASDAQ: CCCC
$2.49+0.01 (+0.61%)
As of Nov 19, 2:46 PM ET

Key statistics

Day range
2.432.64
52-week range
1.695.17
Today
Open2.47
Previous close2.49
Volume—
Valuation
Market cap330.26M
P/E ratio—
EPS (TTM)-0.72
Income & risk
Dividend / yield—
Beta3.27
Avg volume2.57M
Discussion

CCCC News

Stories mentioning CCCC from around the web — every one is an open thread, so give it a like or add your take.

All news →

Loading news…

Financial statements

Financial statements

As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.

Line itemQ1 '26Mar 31Q4 '25Dec 31Q3 '25Sep 30Q2 '25Jun 30Q1 '25Mar 31Q4 '24Dec 31Q3 '24Sep 30Q2 '24Jun 30
Income Statement
Revenue6,15211,01611,2306,4637,2385,17715,36212,006
Cost of Goods Sold
Gross Profit
Operating Expenses
Research & Development24,60624,98225,98926,19727,07232,51331,83823,753
Sales General & Admin
Total Operating Expenses33,93734,16145,64234,96436,40242,88643,60633,448
Operating Income (Loss)(27,785)(23,145)(34,412)(28,501)(29,164)(37,709)(28,244)(21,442)
Interest Income
Interest Expense
Other Expense
Pretax Income(20,365)(32,166)(26,020)(26,322)(34,442)(24,666)(17,716)
Tax Provision0.000.000.00131.000.000.00
Net Income (Loss)(25,129)(20,486)(32,166)(26,020)(26,322)(34,573)(24,666)(17,716)
Earnings Per Share (Basic)(0.20)(0.25)(0.44)(0.37)(0.37)(0.50)(0.35)(0.26)
Earnings Per Share (Diluted)(0.20)(0.25)(0.44)(0.37)(0.37)(0.50)(0.35)(0.26)
Weighted Average Shares Outstanding (Basic)126,07582,89472,56371,00670,83369,37369,62768,810
Weighted Average Shares Outstanding (Diluted)126,07582,89472,56371,00670,83369,37369,62768,810

Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.

Key facts

About CCCC

C4 Therapeutics, Inc. (NASDAQ: CCCC) is a stock listed on the Nasdaq Stock Market under the ticker symbol CCCC. It last traded at $2.49 (Nov 19, 2026, 2:46 PM ET), up 0.6% on the day. That gives C4 Therapeutics a market capitalisation of $330.3M.

Over the past 52 weeks CCCC has traded between $1.69 and $5.17.

Revenue for the quarter ended Mar 31, 2026 was $6.2M; a net loss of $25.1M. Revenue was down 15.0% from $7.2M in the quarter ended Mar 31, 2025.

Last 4 quarters
Quarter endedRevenueNet incomeMargin
Mar 31, 2026$6.2M-$25.1M-408.5%
Dec 31, 2025$11.0M-$20.5M-186.0%
Sep 30, 2025$11.2M-$32.2M-286.4%
Jun 30, 2025$6.5M-$26.0M-402.6%

From C4 Therapeutics’s quarterly (10-Q) filings, in US dollars.

Latest News

Market news from around the web — every story is an open thread, so give it a like or add your take.

All news →

Loading news…